论文部分内容阅读
目的:评价CEF、CMF及卡培他滨用于乳腺癌术后预防乳腺癌复发的经济学效果。方法:82例乳腺癌术后患者分为3组,分别给予CEF、CMF及卡培他滨(CA)的方案进行治疗,观察3组的疗效及不良反应,并进行成本-效果分析。结果:3组方案总有效率分别为75.00%,67.85%,72.72%,总成本分别为27121.76元,16150.30元和30701.20元;成本-效果比分别为361.62,238.02,422.18,CEF组各种不良反应发生率明显高于CMF组及卡培他滨组,差异有显著性(P≤0.05),而CMF组成本-效果比最小。结论:CMF治疗乳腺癌术后预防乳腺癌复发为较佳方案。
Objective: To evaluate the economic effect of CEF, CMF and capecitabine in the prevention of recurrence of breast cancer after operation. Methods: Eighty-two patients with breast cancer were divided into three groups and treated with CEF, CMF and capecitabine respectively. The curative effect and adverse reactions of the three groups were observed and the cost-effectiveness analysis was performed. Results: The total effective rates of the three groups were 75.00%, 67.85% and 72.72% respectively, and the total costs were 27121.76 yuan, 16150.30 yuan and 30701.20 yuan respectively. The cost-effectiveness ratios were 361.62, 238.02 and 422.18 respectively. The adverse reactions The incidence was significantly higher than CMF group and capecitabine group, the difference was significant (P≤0.05), while the CMF group cost - the effect of the smallest. Conclusion: CMF treatment of breast cancer after surgery to prevent recurrence of breast cancer is the best option.